Author

I. Etxeberria

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

C. A. Klebanoff· 2 shared A. Barpanda· 1 shared A. Diaz· 1 shared A. Du· 1 shared A. Saijo· 1 shared A. Wiita· 1 shared A. Yamamichi· 1 shared C. Hong· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

C. A. Klebanoff

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit

F. Yi, T. Cohen, N. Zimmerman, F. A. Dundar, P. Zumbo, R. Eltilib, E. J. Brophy, H. Arkin, J. Feucht, M. V. Gormally, C. S. Hackett, K. N. Kropp, I. Etxeberria, S. S. Chandran, J. H. Park, , C. A. Klebanoff

This study identifies FASLG expression patterns and shows that FAS-L/FAS auto-regulation governs CAR-T and CAR-NK cell persistence, enhancing antitumor efficacy when FAS is inhibited.

bioRxiv · Feb 26, 2024 · PreprintImmunology

Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens

D. W. Kwok, N. O. Stevers, T. Nejo, L. H. Chen, I. Etxeberria, J. Jung, K. Okada, M. Colton Cove, S. Lakshmanachetty, M. Gallus, A. Barpanda, C. Hong, G. K. L. Chan, S. H. Wu, E. Ramos, , H. Okada

The paper identifies tumor-wide splicing aberrations that generate public neoantigens, enabling T-cell-based immunotherapies targeting intratumoral heterogeneity.

bioRxiv · Oct 19, 2023 · PreprintCancer Biology